RecruitingNCT06551129

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

Sponsor

Bristol-Myers Squibb

Enrollment

118 participants

Start Date

May 10, 2024

Study Type

OBSERVATIONAL

Conditions

Obstructive Hypertrophic Cardiomyopathy

Summary

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Participants ≥18 years of age.
Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
Provided informed consent to participate in the study

Exclusion Criteria9

Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
Treated for >7 days with mavacamten by the day of completing the baseline survey
Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
Had stroke or transient ischemic attack within the six-month period prior to the screening
Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe
Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening
Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay
Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening